NEWS: Curebase closes $40M Series B with strategic investment by Gilead. Read about it in TechCrunch, Fierce Biotech, andEndpoints News.
Featured News
2 MIN
February 27, 2023
Curebase appeared in Y Combinator's 2023 list of top private companies where we are noted for our end-to-end clinical trial execution built on cutting-edge software.
Fierce Biotech
May 5, 2022
TechCrunch
Endpoints News
ASCO23: Blue Note and Curebase's DTx reduces cancer-related distress in study
PUBLISHED
Jun 1, 2023
Digging into Digital Therapeutics Trials: Advice for Sites and Sponsors
May 15, 2023
DTx and the case for fit-for-purpose evidentiary standard
Mar 22, 2023
Note to File Podcast: Whitney Stewart, Curebase
May 11, 2023
The Regulatory Landscape of DTx, with Whitney Stewart
March 29, 2023
Advancing the Future of Clinical Trials with Jane Myles
March 2, 2023
The Virtual Shift: Whitney Stewart and Megan Coder on Digital Therapeutics
February 17, 2023
4 MINS
December 6, 2022
Publication provides a foundational set of expectations outlining the necessary clinical evidence to enable appropriate and efficient assessment reflective of the unique nature and innovation cycles of DTx products
5 MINS
December 13, 2022
December 1, 2022
November 15, 2022
Interested in staying up to date with Curebase's latest developments in the decentralized clinical trial space? Get regular updates on news, webinars, blogs and more by subscribing here.
.svg)
%201.svg){kind=logo}
.jpg)
.svg)
.jpg)
.svg)
.jpg)
